Vertex Pharma (VRTX) Tops Q1 EPS by 14c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Vertex (VRTX) PT Raised to $202 at RBC Capital
April 27, 2018 9:01 AM EDTRBC Capital raised its price target on Vertex (NASDAQ: VRTX) to $202.00 (from $199.00) while maintaining a Outperform rating.
... MoreVertex Pharma (VRTX) Begins Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as Triple Combination Regimen for People with Cystic Fibrosis
April 26, 2018 4:37 PM EDTVertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that it is initiating two Phase 3 studies of VX-445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF). The first Phase 3 study will evaluate approximately 360 people with CF who have one copy of the... More
